Clinical trial
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at…
NCT00253539 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00253539 |
|---|---|
| Title | Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer |
| Official title | A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2) |
| Intervention type | Drug, Other |
| Interventions | arzoxifene hydrochloride, tamoxifen citrate, placebo |
| Enrollment | 3 |
| Start date | Jan 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Nov 15, 2005 |
| Last update posted | Apr 13, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: